close
Total Points: 1931
close
Edit Partner Bio
close
Add Position
close
Add Education
close
Profile
close
Profile
close
Partner Description
close
FOLLOWERS ()
close
Edit your post
close
EDIT APPLICATION
close
Start a Talk
Share articles, books, podcasts, ideas or questions that you think are important for other professionals to stay fresh and relevant.
close
Andrei Blasko, PhD, FRSC
Pharmaceutical Executive: Unique dual Pharmaceutical Expertise in both Drug Discovery and Drug Development at Convetit/Currnt
Comments
Keep the conversation going
Andrei Blasko, PhD, FRSC
Pharmaceutical Executive: Unique dual Pharmaceutical Expertise in both Drug Discovery and Drug Development at Convetit/Currnt
Joined 06/05/2017
Level: LEVEL 01 (12 mo pts: 0 pts)
Rating: 5/5 stars (104 ratings)
Lifetime points: 1931 pts
Recognized Pharmaceutical Industry leader, expert at both discovering and developing new drugs (small molecules and biologics). 20+ years of experience inspiring creation of optimal formulations with breakthrough approaches.
Advance drug substance candidates’ strategies, leading discovery teams in profiling and assessing physicochemical properties of the drug candidates, providing feedback to medicinal chemistry on molecular structural liabilities, and facilitating compound transitions to development, including Phase I/II clinical trials and Phase III registration.
Member of Senior Leadership Team with large & small company experience: Roche; Sugen/Pharmacia/Pfizer; Celera; Pain Therapeutics; and Novartis Pharmaceuticals Corporation.
Advance drug development innovation, influencing company vision by strengthening research operation, partnering collaboratively with CEOs, VPs, CROs, and field experts, on cross-disciplinary teams and through independent contributions. Increase shareholders’ values by developing multimillion-dollar products that improve patients’ lives, with marketed product successes such as SUTENT®, a leading VEGF inhibitor for renal cell carcinoma.
Advance drug substance candidates’ strategies, leading discovery teams in profiling and assessing physicochemical properties of the drug candidates, providing feedback to medicinal chemistry on molecular structural liabilities, and facilitating compound transitions to development, including Phase I/II clinical trials and Phase III registration.
Member of Senior Leadership Team with large & small company experience: Roche; Sugen/Pharmacia/Pfizer; Celera; Pain Therapeutics; and Novartis Pharmaceuticals Corporation.
Advance drug development innovation, influencing company vision by strengthening research operation, partnering collaboratively with CEOs, VPs, CROs, and field experts, on cross-disciplinary teams and through independent contributions. Increase shareholders’ values by developing multimillion-dollar products that improve patients’ lives, with marketed product successes such as SUTENT®, a leading VEGF inhibitor for renal cell carcinoma.
close
Edit your Comment